Treatment with cinacalcet of XXXX after renal transplantation.

@entity1 @entity3747 @entity2741 @entity3873 @entity3528 @entity740 @entity460 @entity2742 @entity461 @entity560
BACKGROUND: The treatment of posttransplant @entity3528 ( @entity3528 ) with @entity560 analogues is determined by their effectiveness to reverse @entity2741 . Calcimimetics inhibit @entity461 ( @entity461 ) secretion by modulating the @entity460 -sensing receptor in the parathyroid gland. Cinacalcet, a calcimimetic drug, has proven its effectiveness for the treatment of @entity3528 among @entity1 in phase V of @entity740 . @entity1 AND METHODS: This retrospective analysis included 48 @entity1 with @entity3528 who were treated with cinacalcet. The initial dose of 30 mg/d could be increased to 180 mg, administering @entity3873 also, depending on the serum @entity460 and @entity461 levels. The objectives were a @entity461 level between 75 and 125 pg/mL or a decrease >40%, and a serum @entity460 level below 10.5 mg/dL. RESULTS: The average @entity461 at baseline was 244 pg/mL, decreasing to 131 pg/mL at 1 year (P < .01). The average @entity460 at baseline was 10.1 mg/dL descending to 9.2 mg/dL at 1 year (P < .01). Among @entity1 with @entity2741 , the @entity460 decreased from 11 to 9.6 mg/dL at 1 year (P < .01). Seventy percent of @entity1 without @entity2741 reached the desired value of @entity461 , and 100% of those with @entity2741 . Among @entity1 with @entity2741 , the desired @entity460 level was reached in 91% of cases. Ten @entity1 developed @entity3747 . In 3 cases we stopped the treatment with cinacalcet due to digestive intolerance. CONCLUSIONS: Treatment with cinacalcet controlled @entity2742 and @entity2741 among @entity1 with posttransplant @entity3528 . It was a safe drug, with a low incidence of side effects.
